Zeidan, A., Wang, Y., Yu, R., Matusevich, A., Zhao, R. (2025). Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L). Blood. https://doi.org/10.1182/blood-2025-8176